Agios Pharmaceuticals Q3 2026 Earnings Report

Agios Pharmaceuticals EPS Results

• Actual EPS: N/A
• Consensus EPS: -$1.21
• Beat/Miss: N/A
• One Year Ago EPS: N/A

Agios Pharmaceuticals Revenue Results

• Actual Revenue: N/A
• Expected Revenue: $53.81 million
• Beat/Miss: N/A
• YoY Revenue Growth: N/A

Agios Pharmaceuticals Announcement Details

• Quarter: Q3 2026
• Date: 10/29/2026
• Time: Before Market Opens
• Conference Call Date: Thursday, October 29, 2026
• Conference Call Time: 8:00AM ET

Agios Pharmaceuticals (NASDAQ:AGIO) is a biopharmaceutical company focused on discovering and developing medicines for rare diseases, with an emphasis on disorders involving cellular metabolism. The company’s research has centered on small-molecule therapies designed to address underlying biological mechanisms rather than only treating symptoms.

Agios’ principal commercial product is Pyrukynd (mitapivat), an oral activator of pyruvate kinase approved in the United States and other markets for the treatment of hemolytic anemia associated with pyruvate kinase deficiency in adults. The company is also evaluating mitapivat and other investigational therapies for additional rare blood disorders, including sickle cell disease and thalassemia.

Founded in 2008 and headquartered in Cambridge, Massachusetts, Agios initially developed a broad oncology pipeline based on cancer metabolism. It later transferred its oncology business to Servier, retaining certain rights and economic interests, and shifted its strategic focus toward rare diseases. Agios’ products and clinical programs are intended for patients in the United States and international markets, supported by regulatory and commercial partnerships where applicable. Brian Goff serves as the company’s chief executive officer.